Drug Profile
GTL 001
Alternative Names: CyAa-HPV-16E7 CyaA-HPV-18E7 vaccine; GTL001; HPV 16E7 HPV 18E7 protein vaccine; HPV 16E7-HPV 18E7; ProCervixLatest Information Update: 06 Nov 2020
Price :
$50
*
At a glance
- Originator GENTICEL
- Developer GenKyoTex; GENTICEL
- Class Papillomavirus vaccines; Protein vaccines; Recombinant proteins; Synthetic vaccines
- Mechanism of Action CD4-positive T lymphocyte stimulants; CD8 positive T lymphocyte stimulants; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Oropharyngeal cancer
- Discontinued Anal cancer; Cancer; Cervical cancer; Human papillomavirus infections
Most Recent Events
- 03 Nov 2020 GenKyoTex has been acquired by Calliditas Therapeutics
- 28 Dec 2019 No recent reports of development identified for preclinical development in Oropharyngeal-cancer(Prevention) in France (Parenteral)
- 13 Dec 2016 Final efficacy and adverse events data from the phase II RHEIA-VAC trial in Cervical cancer released by Genticel